Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Cash from Financing Activities (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Cash from Financing Activities for 3 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 85.61% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, up 76.12% year-over-year, with the annual reading at $7.3 million for FY2025, 76.12% up from the prior year.
  • Cash from Financing Activities hit $2.1 million in Q4 2025 for Mangoceuticals, up from $1.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $5.0 million in Q1 2023 to a low of $267500.0 in Q1 2024.
  • Historically, Cash from Financing Activities has averaged $1.7 million across 3 years, with a median of $1.3 million in 2025.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 94.65% in 2024 and later skyrocketed 754.21% in 2025.
  • Year by year, Cash from Financing Activities stood at $1.2 million in 2023, then decreased by 6.46% to $1.1 million in 2024, then skyrocketed by 85.61% to $2.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for MGRX at $2.1 million in Q4 2025, $1.6 million in Q3 2025, and $1.3 million in Q2 2025.